Paul Industries delivers CIP/SIP systems for pharmaceutical manufacturers as a single-source supplier and installer. We design, fabricate, install, passivate, and validate CIP/SIP systems – the clean-in-place and steam-in-place circuits that sterilize and clean a process train without disassembly – built to the standards your process and your auditors require.
What pharmaceutical manufacturers need from cip/sip systems
Pharmaceutical manufacturing lives and dies by cGMP compliance – FDA 21 CFR Parts 210/211, validated systems, and audit-ready documentation. Whether the process is oral solid dose, sterile injectables, or API synthesis, the utilities behind it (process water, clean steam, sanitary piping, CIP/SIP) have to be designed, installed, and documented to survive an FDA inspection.
For this work, that means cGMP (21 CFR 210/211) compliance, validated IQ/OQ/PQ turnover, USP-monograph water quality, and fully documented, traceable installations – not as an afterthought, but engineered in from the first drawing.
What we deliver
- Clean-in-place (CIP) skids – single-use or recirculating, with spray-device coverage engineered for full wetted-surface contact
- Steam-in-place (SIP) circuits designed for condensate removal, sterilization hold, and validated F0 delivery
- Integration with your process piping so CIP/SIP loops actually reach every dead-leg and instrument
- Cycle development and documentation to support cleaning and sterilization validation
- Controls and recipe management for repeatable, auditable cycles
One accountable partner
Most pharmaceutical projects get split between an equipment supplier and an install contractor – and the validation burden falls in the gap between them. Paul Industries closes that gap by self-performing the whole scope, from supply through documented turnover.
Related: CIP/SIP Systems services · Pharmaceutical Manufacturers solutions · Request a quote
Frequently asked questions
Why do pharmaceutical plants require CIP/SIP systems?
Pharmaceutical manufacturing must prevent active-ingredient carryover and microbial contamination between products and batches. Automated CIP delivers documented, repeatable cleaning while SIP sterilizes equipment, giving the validated contamination control that FDA cleaning-validation expectations demand across oral, sterile, and API operations.
How does CIP/SIP apply to sterile fill-finish?
Sterile fill-finish equipment, holding tanks, and product lines must be both cleaned and sterilized before aseptic filling. CIP removes residues; SIP sterilizes the fluid path to a validated hold. Paul Industries designs the coverage and steam routing that fill-finish sterility assurance depends on.
Is CIP used for oral solid dose manufacturing?
Oral solid dose lines still need validated cleaning of granulation, coating, and liquid-prep equipment to prevent cross-contamination between products. CIP automates that on tanks and closed equipment, while dedicated wash approaches handle other units. Paul Industries scopes cleaning to each dosage-form’s equipment.
How is cleaning validation handled for pharmaceutical CIP?
Cleaning validation sets residue acceptance limits (often via MACO calculations for the active ingredient), then proves the CIP cycle meets them with swab and rinse sampling plus riboflavin coverage testing. Paul Industries builds systems and protocols that produce inspection-ready cleaning-validation evidence.
What is MACO and how does it affect CIP design?
MACO (Maximum Allowable Carryover) is the residue limit of one product permitted into the next, based on toxicity and batch size. Tighter MACO limits demand better coverage, hotter cycles, and thorough rinsing. CIP cycles are engineered to reliably meet the calculated limit.
How does CIP/SIP prevent cross-contamination in multi-product pharma facilities?
Shared equipment running different drugs must be cleaned to validated carryover limits between products. CIP delivers documented cleaning per changeover and SIP re-sterilizes, so no active ingredient or microbe carries into the next batch. Paul Industries designs for validated product-to-product changeover.
What FDA expectations apply to pharmaceutical CIP/SIP?
FDA expects documented, reproducible cleaning with scientifically justified limits and validated sterilization, all under cGMP. Systems must show coverage, drainability, and executed IQ/OQ/PQ. Paul Industries builds and validates to those expectations. Call 201-450-8280.
How are API and drug-substance systems cleaned?
API equipment can carry potent or hard-to-remove compounds requiring aggressive, validated cleaning chemistry and low residue limits. CIP circulates heated caustic and acid with proven coverage, followed by rinse sampling to confirm limits. Paul Industries develops chemistry matched to the specific API soil.
What water quality feeds pharmaceutical CIP rinses?
Final rinses typically use USP Purified Water or WFI so cleaning does not leave ionic or microbial residue on product-contact surfaces. Clean steam for SIP is generated from purified feedwater. Paul Industries integrates CIP/SIP with the compliant water and steam systems supplying them.
How is SIP validated for pharmaceutical equipment?
SIP validation confirms every surface reaches and holds sterilization temperature. Thermocouple mapping and biological indicators verify the hold at cold spots, with condensate drainage and air removal proven. IQ/OQ/PQ document repeatable sterilization across the equipment train.
What standards govern pharmaceutical CIP/SIP construction?
Product-contact fabrication follows ASME BPE, passivation follows ASTM A967/A380, and water quality references USP <1231>, all under cGMP and FDA expectations. Together these ensure cleanable, corrosion-resistant, fully drainable surfaces. Paul Industries fabricates and validates against each of these standards.
Can CIP/SIP be added to an existing pharmaceutical line?
Yes. Automated CIP/SIP can retrofit onto existing tanks, reactors, and product lines through tie-in engineering scheduled around production. Paul Industries plans retrofits during shutdowns to limit downtime while upgrading a manual line to validated automated cleaning.
What causes pharmaceutical cleaning validation to fail?
Failures usually trace to incomplete spray coverage, dead legs, poor drainage, or cycle parameters too weak for the active ingredient’s solubility. Paul Industries diagnoses whether the cause is mechanical or cycle-based and corrects it at the source. Call 201-450-8280.
How does CIP/SIP support potent-compound (HPAPI) handling?
Highly potent APIs demand very low carryover limits and often containment-integrated cleaning. CIP cycles use validated chemistry and thorough rinsing to hit stringent MACO values, with coverage proven by testing. Paul Industries engineers cleaning around the potency and containment requirements.
How long does pharmaceutical CIP/SIP validation take?
Validation duration depends on the number of products, worst-case bracketing, and PQ run requirements. Multi-product lines with tight limits need more sampling and runs. Paul Industries scopes the protocol timeline after reviewing your product matrix and equipment.
How do I start a pharmaceutical CIP/SIP project?
Share your product matrix, active-ingredient data, P&IDs, and cleaning and sterility limits. Paul Industries engineers coverage and steam routing, calculates against carryover limits, then fabricates to ASME BPE, installs, and validates as one accountable contractor. Call 201-450-8280 to begin.
What pharmaceutical requirements do you build to?
Our cip/sip systems work for pharmaceutical manufacturers is built around cGMP (21 CFR 210/211) compliance, validated IQ/OQ/PQ turnover, USP-monograph water quality, and fully documented, traceable installations. Every installation ships with the documentation your quality team needs.
Get a single-source quote
Paul Industries designs, fabricates, installs, passivates, and validates – one accountable partner instead of a vendor plus a contractor plus a validation firm. Tell us about your project and we will scope it.
What do pharmaceutical CIP and SIP systems have to achieve?
| Requirement | What it means |
|---|---|
| Cleaning objective | Removal of product residue to a validated acceptance limit, with carryover calculated |
| Sterilisation objective | SIP of product-contact surfaces using clean steam meeting EN 285 |
| Coverage | Spray device coverage proven, not assumed — riboflavin or equivalent |
| Velocity | Maintained at the FURTHEST point of the circuit, not at the skid outlet |
| Drainability | Full gravity drainage; retained solution defeats both CIP and SIP |
| Chemistry | Single-use or recirculated, with concentration verified in line |
| Records | Cycle data with audit trail under 21 CFR Part 11 |
| Validation | Cleaning validation with worst-case soil and hardest-to-clean location identified |
Do you handle validation, or just installation?
Both. In pharmaceutical manufacturing the cleaning validation carries more weight than the equipment, because a multi-product plant must demonstrate that residue from one product cannot reach an unacceptable level in the next, for every pairing in the matrix. Paul Industries performs the coverage testing, develops and documents the cycle recipes, executes the validation runs, and supports the carryover calculation derived from health-based exposure limits and shared surface area. We also set up the ongoing verification, meaning rinse conductivity, total organic carbon and periodic swabbing, that carries the validated state between formal revalidations. Installation without that evidence leaves the plant unable to defend its changeover.
Can you take a project from design through startup?
Yes. For a pharmaceutical plant the value of a single contract from design to startup is that the acceptance limit drives the design rather than being discovered afterwards. The worst-case product, its health-based exposure limit and the smallest subsequent batch size together set a residue limit per square centimetre, and that number determines spray device selection, circuit routing and cycle severity. Designing the skid first and calculating the limit later is how plants end up with a cleaning system that cannot reach its own acceptance criterion. We establish the limit at design stage and build backwards from it.